信迪利单抗结合GP方案化疗对晚期NSCLC患者血清VEGF、BFGF水平及免疫指标的影响

doi:10.3969/j.issn.1001-8131.2025.06.005

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (433 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the combined use of sintilimab and gemcitabine+cisplatin(GP) regimen chemotherapy in advanced non-small cell lung cancer. Methods 78 patients with advanced NSCLC were categorized into two groups with random numerical table.The patients of control group were administrated GP regimen,and on this basis,the patients of observation group additionally took sintilimab.The comparisons were made on clinical therapeutic effect,tumor growth factors,tumor markers,immune indicators,and adverse reactions in both groups. Results The ORR of the observation group was higher than the control group(P>0.05),while the DCR was higher,with statistical difference(P<0.05); The observation group had lower levels of vascular endothelial growth factor(VEGF),basic fibroblast growth factor(BFGF),carcinoembryonic antigen(CEA),and T cell subset CD8⁺ and higher CD4⁺ compared with the control group after treatment(P<0.05); The comparisons of adverse reactions in both groups expressed no statistical difference(P>0.05). Conclusion The combination of sintilimab and GP regimen chemotherapy can reduce serum tumor growth factors and tumor markers in patients with advanced NSCLC,and improve immune indicators,which is safe and controllable.

Key words： Non small cell lung cancer advanced sintilimab gemcitabine cisplatin immune indicators indicators

Received: 10 July 2025

PACS:

R392.6

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhang Yueliang
	Gan Huizhen
	Lin Hui'e
	Huang Honghong

Cite this article:

Zhang Yueliang,Gan Huizhen,Lin Hui'e, et al. The Effect of Sintilimab Combined with GP Regimen Chemotherapy on Serum VEGF,BFGF Levels and Immune Indicators in Advanced NSCLC Patients[J]. journal1, 2025, 45(6): 18-20.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2025.06.005 OR http://www.hrbyybjb.org.cn/EN/Y2025/V45/I6/18

[1] 杨敏伟,曾冬香,杨全良,等.信迪利单抗在晚期非小细胞肺癌化疗患者中的应用及对其血清细胞因子、免疫功能的影响[J].中国临床药理学杂志,2022,38(24):2931-2935.
[2] 黄纯碧,李卫平,许汝福,等.吉西他滨联合顺铂治疗晚期非小细胞肺癌的系统评价再评价[J].中国药房,2022,33(5):622-627.
[3] 李国强,席孝忠,陈洋.吉西他滨和顺铂新辅助化疗联合手术治疗非小细胞肺癌的临床观察[J].实用癌症杂志,2023,38(9):1533-1535,1539.
[4] 杨艳莉,刘红梅,余静丽.信迪利单抗对晚期非小细胞肺癌患者T淋巴细胞亚群的影响及其治疗效果研究[J].癌症进展,2023,21(3):301-304,308.
[5] 陈良新,孙鹏,胡中舟.信迪利单抗联合化疗对晚期非小细胞肺癌肿瘤标志物及免疫功能的影响[J].检验医学与临床,2022,19(8):1106-1108.
[6] 中华医学会,中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2018版)[J].中华肿瘤杂志,2018,40(12):935-964.
[7] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90,111.
[8] 冉方兰,张孝彬,卢安静,等.特瑞普利单抗注射液联合长春瑞滨+顺铂化疗一线治疗晚期NSCLC的效果及对外周血淋巴细胞PD-1变化的影响[J].实用药物与临床,2022,25(11):981-985.
[9] 赵明燕,胡述博,楚旭,等.人参皂苷Rh2联合顺铂+培美曲塞化疗治疗晚期肺癌的疗效[J].癌症进展,2022,20(24):2553-2556.
[10] 王实慧,汤姝.埃克替尼联合吉西他滨、顺铂化疗对晚期非小细胞肺癌患者血管新生和治疗获益的影响[J].中国医院药学杂志,2024,44(11):1317-1321.
[11] 李银英,郭丽芳,周建华,等.紫杉醇脂质体联合顺铂治疗晚期NSCLC的效果及对肿瘤标志物、近期预后的影响[J].临床医学,2023,43(5):88-91.